ZNTLZentalis Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Zentalis Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZNTL본 종목 | $221M#9 | — | 1.5x#7 | — | -100.0%#9 | 17.4%#7 | — | -95.4%#11 | — | — | 116.9%#1 | — |
| GLSI | $255M#2 | — | 81.8x#13 | — | — | -11.2%#12 | — | -621.1%#13 | — | — | — | — |
| FHTX | $250M#3 | — | — | 8.1x#5 | 36.8%#3 | 14.2%#8 | -279.5%#5 | — | — | — | -13.4%#6 | — |
| AKBA | $244M#4 | — | 9.8x#12 | 1.0x#3 | 47.5%#2 | 92.4%#4 | 9.9%#3 | -21.2%#6 | — | — | — | — |
| ALXO | $241M#6 | — | 1.8x#10 | — | — | 24.6%#6 | — | -74.7%#9 | -84.4%#2 | — | — | — |
| RNAC | $242M#5 | — | — | 605.5x#9 | -99.0%#8 | -68.3%#15 | -35851.3%#9 | — | — | — | — | — |
| WHWK | $235M#7 | — | 1.3x#5 | 32.9x#7 | -72.5%#7 | 67.7%#5 | -1601.1%#8 | -11.3%#5 | — | — | 110.2%#2 | — |
| NATR | $232M#8 | 13.2x#2 | 1.7x#9 | 0.5x#1 | 5.7%#5 | 153.7%#2 | 5.2%#4 | 14.3%#2 | — | 9#1 | -19.9%#7 | — |
| SIGA | $220M#10 | — | 1.3x#6 | 2.3x#4 | -31.8%#6 | -60.7%#14 | 25.1%#2 | 14.1%#3 | — | — | -57.8%#9 | 19.6%#1 |
| KROS | $220M#11 | — | 0.8x#2 | 0.9x#2 | 6775.0%#1 | 146.4%#3 | 27.7%#1 | 33.2%#1 | — | — | -28.9%#8 | — |
| ELDN | $215M#12 | — | 6.5x#11 | — | — | -26.1%#13 | — | -138.2%#12 | — | — | — | — |
| BRVE | $2.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| NKTX | $201M#14 | — | 0.8x#1 | — | — | 4.3%#10 | — | -42.0%#7 | — | — | 45.8%#5 | — |
| PEPG | $202M#13 | — | 1.7x#8 | — | — | 0.4%#11 | — | -75.0%#10 | — | — | 55.6%#4 | — |
| ORMP | $196M#15 | 1.1x#1 | 1.0x#4 | 97.8x#8 | — | 573.1%#1 | -754.4%#6 | 0.0%#4 | -4.4%#1 | — | 106.6%#3 | — |
| TNXP | $195M#16 | — | 0.9x#3 | 14.9x#6 | 29.8%#4 | 4.6%#9 | -959.1%#7 | -55.8%#8 | -234.8%#3 | — | -58.9%#10 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice